FDA Approved: LUCENTIS — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for LUCENTIS (ranibizumab) from Genentech, Inc., modifying the existing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema Following Retinal Vein Occlusion
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

SUPPL AP for LUCENTIS (RANIBIZUMAB)